tbuckley/cabot-search huggingface dataset:
Abstract 2758: Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of C-Jun N-terminal kinase activation
Authors: Hairong Cheng, Bo Hong, Lanlan Zhou, Joshua Allen, David Dicker, Wafik El-Deiry
Journal: Cancer Research (2012)

Abstract Discovery of the molecular targets of chemotherapeutic medicines and their chemical footprints can validate and improve the use of such medicines. In the present study, we investigated the effect of mitomycin C (MMC), a well-known chemotherapeutic agent on cancer cell apoptosis induced by TRAIL. We found that MMC not only potentiated TRAIL-induced apoptosis in HCT116 (p53-/-) colon cancer cells but also sensitized TRAIL-resistant colon cancer cells HT-29 to the pro-apoptotic cytokine. MMC also improved the pro-apoptotic effects of two TRAIL receptor agonists, the antibodies mapatumumab and lexatumumab. At a mechanistic level, MMC downregulated cell survival proteins including Bcl2, Mcl-1 and Bcl-XL, upregulated cell pro-apoptotic proteins including Bax and Bim, and induced the cell surface expression of TRAIL death receptors DR4 and DR5. Gene silencing of DR5 by short hairpin RNA reduced the apoptosis induced by combination treatment of MMC and TRAIL. Induction of DR4 and DR5 was independent of p53, Bax and Bim, but was dependent on c-Jun N-terminal kinase (JNK) as JNK pharmacologic inhibition and the JNK siRNA abolished the induction of the TRAIL receptors by MMC. The results provide insights into strategies for the development of novel combinatorial cancer therapy combinations that may be further tested in the clinic. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2758. doi:1538-7445.AM2012-2758
P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION
Authors: T. Hassanein, K. Sims, M. Bennett, N. Gitlin, E. Lawitz, T. Nguyen, L. Webster, Z. Younossi, H. Schwartz, P.J. Thuluvath, H. Zhou, B. Rege, F. McPhee, N. Zhou, M. Wind-Rotolo, E. Chung, A. Griffies, D. Grasela, D.F. Gardiner
Journal: Journal of Hepatology (2014)
AB0279 Study of Peptidyl Arginine Deiminases 4 (PAD 4) Antibodies in Rheumatoid Arthritis (RA) Patients
Authors: N. Mohannad, D.A. Hallous, M.A.E.N. Kamel, E.S.H. Radwan
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> A "window of opportunity" exists in early RA. Autoantibodies against citrullinated proteins catalyzed by PADs are often detected in patients with RA. They are produced early &amp; are more specific than rheumatoid factor (RF).Anti-PAD 4 antibodies are specific markers of RA, independently associated with more severe disease. Autoantibodies to PAD-4 are present during the preclinical phase of RA in a subset of patients (pts). <h3>Objectives</h3> to study the presence of anti PAD-4 in early RA pts (&lt;2 years) &amp; first degree relatives and its relation to disease activity &amp; extra-articular involvement <h3>Methods</h3> BMI,CBC,kidney functions, ESR, CRP, RF, Anti-CCP, Anti-PAD4 were assessed in 40 RA pts, 20 first degree relatives &amp; 20 matched controls. DAS 28 calculated in RA pts, pts with history of renal, cardiac or liver dysfunction were excluded <h3>Results</h3> It was observed that: highly significant increase in anti-PAD4 in RA group (gp)than controls, &amp; in female relatives than control females, significant increase anti-CCP in RA pts &amp; in relatives gp than the control gp. The sensitivity of anti-CCP alone was 87.5%, anti-PAD4 alone 60%, combining the two markers the sensitivity rose to 97.5%. The specificity of anti-CCP was 95%, of anti-PAD4 was 90%, on combining the two it reached 100% in controls. No significant difference between positive and negative anti-PAD4 RA pts regarding DAS28. RF and anti-CCP show a significant increase in positive anti-PAD4 pts than the negative ones. ESR &amp; CRP show no significant difference in both positive and negative anti-PAD4 pts. The number of tender joints (TJC) and swollen joints, morning stiffness was higher in anti-PAD 4 pts but not to the level of significance, disease duration show no significant difference between the positive and negative anti-PAD4 pts. A positive significant correlation between: anti-PAD4 and DAS 28 score (r= +0.43, P=0.006), between anti-PAD4 and anti-CCP (r=0.819, p=0.0001). between anti-PAD4 and RF (r=0.6, p=0.0001), and between Anti-PAD4 and TJC (r=0.50, p&lt;0.001) in RA pts was observed. As most of 9 pts had early RA no significant extra-articular manifestations <h3>Conclusions</h3> Significant increase in anti-PAD4 in RA &amp; their relatives -female ones- than controls. Sensitivity &amp; specificity of anti-CCP increased in the presence of anti-PAD4. Anti-PAD4 was correlated with RF, anti-CCP &amp; disease activity reflected by DAS 28 &amp; TJC <h3>References</h3> Roth EB, et al. Antibodies against transglutaminases, peptidylargininedeiminase and citrulline in RA – new pathways to epitope spreading. Clin Exp Rheumatol 2006; 24:12-8 <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1078
P04.01 * RELA FUSION DEFINES CLINICOPATHOLOGIC SUBSETS OF SUPRATENTORIAL EPENDYMOMA: A STUDY FROM THE COLLABORATIVE EPENDYMOMA RESEARCH NETWORK
Authors: K. Wani, E. Vera-Bolanos, T. Armstrong, S. Pfister, D. Jones, H. Witt, K. Pajter, M. Kool, M. Gilbert, K. Aldape
Journal: Neuro-Oncology (2014)

A novel fusion involving C11ORF95 and RelA was recently described in supratentorial ependymomas. We sought to further characterize the clinical relevance of this fusion. We evaluated a cohort of 98 supratentorial ependymomas from the collaborative ependymoma research network (CERN) tissue repository. Screening of fusion transcripts from FFPE-derived RNA for the 2 most common fusion breakpoints (representing over 90% of cases when a fusion is present), we found 30 fusion-positive cases and 68 cases in which either fusion transcript was not present. With a goal of comparing fusion-positive vs. fusion negative cases, we found that fusion positive-cases were most likely to be diagnosed as anaplastic-grade III compared to fusion-negative cases (67% vs. 41%, respectively). The median patient age of fusion-positive cases was younger than fusion-negative cases (9.5 vs. 24.7 years). Overall, 20/52 (38%) of pediatric cases (age <21), were fusion-positive, compared with 10/46 (22%) of adult cases. Patient outcomes (overall- and progression-free survival) were not significantly different between fusion-positive and fusion-negative cases. Thirty-six of the 98 cases included in this study were examined for changes in DNA copy number (using Oncoscan, performed by Affymetrix) showing that patterns of copy number changes differed based on fusion status: losses in 9p, 11q and 14q and gains of 16q were significantly more common in fusion- positive cases. Conversely gains in 12, 18q and 20p were more common in fusion-negative cases: for example, loss of 9p was found in 38% of fusion-positive cases but only 6% of fusion-negative cases; conversely gain of 12q was not found in fusion-positive cases but was present in 30% of fusion-negative cases. Overall, this study extends the findings of the RelA fusion in supratentorial ependymoma by showing that it is nearly twice as common in pediatric cases, tends to present more frequently as WHO grade III and exhibits distinct patterns of DNA copy number aberration. These results identify clinical, pathologic and molecular correlates of RelA fusion status and extends the findings originally reported to robustly to define 2 major molecular subgroups of supratentorial ependymoma.
Abstract 3177: Web-based access using CellMiner for gene expression, DNA copy number, microRNA transcript levels, variant status, drug activity, and their pattern comparisons for the NCI-60.
Authors: William C. Reinhold, Margot Sunshine, Sudir Varma, Hongfang Liu, Ogan Abaan, Paul Meltzer, Joel Morris, Kurt Kohn, James Doroshow, Yves Pommier
Journal: Cancer Research (2013)

Abstract High-throughput data is increasingly being integrated into the fields of biology, molecular biology, and pharmacology. However, a difficult problem has been the rapid and fluid access to and integration of the data, which tends to reside in huge unwieldy databases. One set of cell lines with substantial potential for benefit from this type of access and integration is the NCI-60 cancerous cell lines. We present here a set of tools within our CellMiner web-application designed to address this need for the areas of transcript expression, microRNA expression, gene DNA copy number, variant status, and drug activity. CellMiner allows the user to rapidly access data for relative levels of transcript expression for 26,065 genes, 360 microRNAs, and 20,602 compounds including 102 Food and Drug Administration (FDA)-approved drugs. These levels in turn create patterns across the NCI-60 that can be compared to one another using our “pattern match” tool. Together, these tools allow one to query the data for potential relationships between these parameters, in a manner specific to a users area of expertise and interest, in a rapid and flexible manner without the need for expertise in computer science or bioinformatics. Comparisons of transcript/drug will be demonstrated with SLFN11/topotecan; variant/drug with BRAF V600E/vemurafinib; colon tissue-of origin specific genes with TRIM15, RNF43, and VIL1; and DNA copy number change with CDKN2A (p16). The data are publicly available at http://discover.nci.nih.gov/cellminer. Citation Format: William C. Reinhold, Margot Sunshine, Sudir Varma, Hongfang Liu, Ogan Abaan, Paul Meltzer, Joel Morris, Kurt Kohn, James Doroshow, Yves Pommier. Web-based access using CellMiner for gene expression, DNA copy number, microRNA transcript levels, variant status, drug activity, and their pattern comparisons for the NCI-60. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3177. doi:10.1158/1538-7445.AM2013-3177
Detection of a Sphenoid Bone Metastasis Using Tc-99m MDP Bone SPECT of the Skull
Authors: PINAR OZGEN, MARK W. GRAVES, BRUCE ZUKERBERG, MANISH GOYAL, ALICE SCHEFF
Journal: Clinical Nuclear Medicine (1996)

SPECT is used to improve the lesion to background ratio of abnormalities superimposed on contiguous normal structures. Bone SPECT imaging of the skull has been employed in temporomandibular joint disease, Paget's disease, tumors, and infectious processes. The authors present the case of a 32-year-old man with Ewing's sarcoma and a new left 3rd nerve palsy. The bone scan performed for metastatic evaluation showed a subtle facial asymmetry on the planar skull images. The skull SPECT revealed intense focal uptake in the sphenoid bone and correlated closely with the area of tumor infiltration evident on magnetic resonance imaging.
Imaging Product Wins Approval
Authors: J. Bowersox
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Imaging Product Wins Approval Get access John Bowersox John Bowersox Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 3, 3 February 1993, Pages 187–188, https://doi.org/10.1093/jnci/85.3.187 Published: 03 February 1993
SAT0039 A Prediction Rule for Sustained Remission of Rheumatoid Arthritis
Authors: Y. Haji, M. Kishimoto, R. Rokutanda, C. Min, Y. Ohara, Y. Suyama, H. Shimizu, K.-I. Yamaguchi, G. A. Deshpande, S. Ohde, A. Takeda, Y. Matsui, T. Matsui, J. Nishino, M. Okada, S. Tohma
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Sustained remission is an important goal to of therapy in rheumatoid arthritis (RA). In daily clinical practice, RA patients in remission are assessed by various clinical outcomes. <h3>Objectives</h3> The purpose of this study is to identify clinical prognostic factors for sustained remission and build a predictive model from a large cohort database. <h3>Methods</h3> Data from RA patients registered in a nationwide Japanese cohort database (<i>NinJa</i> : National Database of Rheumatic Diseases by iR-net in Japan) in 2009 and 2010 were used to evaluate baseline characteristics, treatment profiles, and the following clinical outcomes: tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP), ESR, Visual Analog Scale (VAS), pain VAS, patient VAS, physician VAS, and Modified Health Assessment Questionnaire (MHAQ). All patients with SDAI remission in 2009 were categorized based on whether remission was maintained in 2010. A multivariate Cox regression model was constructed for predictive factors and a prognostic prediction model was constructed. <h3>Results</h3> We enrolled 4215 patients in 2009 of whom 930 patients had SDAI remission. After 1 year, 623 patients (67.0%) had sustained remission. Compared to non-sustained remission group, disease duration, presence of erosion, SJC, CRP, ESR, VAS, pain VAS, physician VAS, and MHAQ were significantly lower in the sustained remission group (p&lt;0.05). A prognostic prediction model with a total score of 4 points for remission failure after 1 year was constructed as follows: 2 points for MHAQ &gt;1, and 1 point each for presence of erosion and SJC &gt;1. For a total scores of 0, 1, 2, 3, and 4 points, remission failure rates after 1 year are 17.2%, 25.8%, 37.7%, 50.8%, 60.0%, respectively. Area under the receiver operating characteristic (ROC) curve for this model was 66.0% (95% CI: 61.5–70.5%). <h3>Image/graph</h3> <h3>Conclusions</h3> We found that presence of erosion, SJC, and MHAQ were significantly less in those with sustained remission after 1 year. A prediction model was successfully built and validated using clinically relevant parameters. <h3>Disclosure of Interest</h3> None Declared
Differences in the Use of Procedures between Women and Men Hospitalized for Coronary Heart Disease
Authors: J Z Ayanian, A M Epstein
Journal: New England Journal of Medicine (1991)

Previous studies at individual hospitals have reported differences in the use of major diagnostic and therapeutic procedures for women and men with coronary heart disease. To assess whether these differences can be generalized, we performed retrospective analyses of coronary angiography and revascularization (coronary-artery bypass surgery or percutaneous transluminal coronary angioplasty) in women and men hospitalized for coronary heart disease in 1987, using abstract data on 49,623 discharges in Massachusetts and 33,159 discharges in Maryland. We used multiple logistic regression to estimate the adjusted odds of the use of a procedure, controlling for principal diagnosis, age, secondary diagnosis of congestive heart failure or diabetes mellitus, race, and insurance status.
Abstract LB-202: The significance of stress-responsive molecules in cancer stem cells derived from ovarian and endometrial cancer
Authors: Kazuyo Yasuda
Journal: Cancer Research (2012)

Abstract Cancer stem cells (CSC) are characterized by their high tumor-initiating capacity, self-renewal and differentiation. Recent studies have been reported that higher aldehyde dehydrogenase1 (ALDH1) activity represent the characters of CSCs. By using ALDEFLUOR assay, we could successfully isolate stem-like cells from endometrial and ovarian cancer cell lines. ALDH1-high cells expressed stem cell markers, such as SOX-2, Oct-3/4 and Nanog. They showed significantly higher tumorigenicity than ALDH1-low cells in the transplantation test using NOD/SCID mice. Comparative gene expression analysis revealed several characteristic molecules that were expressed preferentially in ALDH1-high cells, including stress-responsive molecules, oxidoreductase and heat shock proteins. It is suggested that high levels of stress-responsive genes may explain at least in part highly stress resistance properties of CSCs. In addition, stress-responsive pathway might become a therapeutic molecular target of CSCs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-202. doi:1538-7445.AM2012-LB-202
LAW &amp;amp;amp; MEDICINE
Authors: Angela Roddey Holder
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mucosal tears and colonic perforation in a patient with collagenous colitis
Authors: Rachel van Eijk, Dirk Bac
Journal: Endoscopy (2014)

Collagenous colitis, which is clinically characterized by chronic non-bloody diarrhea, is a variant of microscopic colitis. It can be diagnosed on histological grounds, with thickening of the subepithelial collagen layer [1] [2] [3]. The colonic mucosa is usually endoscopically normal, although minor abnormalities such as edema or erythema can be seen [2] [3]. Serious complications are rare.
Perfecting Breast-Cancer Treatment — Incremental Gains and Musculoskeletal Pains
Authors: Dawn L. Hershman
Journal: New England Journal of Medicine (2014)

A fundamental feature of adjuvant therapy (treatment of apparently disease-free people to reduce the risk of recurrence) is that many are treated to benefit a few. The options for the adjuvant treatment of hormone-sensitive breast cancer have expanded in recent years. On the basis of meta-analyses of individual-patient data in studies dating back to 1985, tamoxifen has remained the standard of care in breast cancer. Tamoxifen reduces the annual rates of breast-cancer recurrence by almost half and mortality by one third. In absolute terms, this translates to 11.8 fewer recurrences and 9.2 fewer deaths per 100 women at 15 years. . . .
P17.09 * PCV CHEMOTHERAPY IMMEDIATELY FOLLOWED BY RADIOTHERAPY IN DIFFUSE LOW GRADE GLIOMAS - ABOUT A SERIES OF 12 PATIENTS
Authors: M. Blonski, C. Lacroix, P. N. Thi-Lambert, G. Gauchotte, K. Hassani, P. Manceau, M. Ben Abdallah, J. Moureaux, T. Bastogne, L. Taillandier
Journal: Neuro-Oncology (2014)

INTRODUCTION: PCV (procarbazine, CCNU, vincristine) chemotherapy was the first association evaluated in diffuse low grade gliomas (DLGGs). Impact of temozolomide and PCV was previously assessed on growth kinetics. Nevertheless, there are no data concerning the growth kinetics of DLGGs after PCV immediately followed by radiotherapy. METHODS: We retrospectively selected patients with histological diagnosis of DLGGs from a french neuro-oncological center (Nancy) who benefited from PCV chemotherapy immediately followed by conventional radiotherapy. Clinical, neuroimaging (kinetics), pathological and molecular data were recorded. RESULTS: Twelve patients with a median age at diagnosis of 37,9 years (range 24 to 56) were selected. The median follow-up was 17,9 years (range 12,6 to 22,31). The median number of PCV cycles was 5 (range 2 to 6). The median time between the end of PCV chemotherapy and the beginning of the radiotherapy was 2,6 months (range 1 to 5). The median dose of radiotherapy was 54 Gy (range 54 to 60). During the follow-up period, 3 patients died and 3 patients presented anaplastic transformation (median time to transformation 12 years, range 11,8 to 14). The median survival was 18 years (range 12,6 to “not reached”). 2 patients developed severe neurocognitive deficits (dementia) and 1 patient presented a postradiation stroke. 10 DLGG patients had IDH1 R132H mutation, 5 patients showed a surexpression of P53 and 5 expressed alpha-internexin. Before treatment combining PCV and radiotherapy, the median spontaneous growth kinetics was 4,03 mm per year (range 2,32 to 11,26). After the combined treatment, the growth kinetics remain negative in 10 patients with a median of -1,72mm/year (range -5,36 to 1,92). The median duration of negative kinetics was 8,8 years (range 0 to 16,6). CONCLUSIONS: Despite this limited series, we reported growth kinetics data on the synergy of PCV and radiotherapy in DLGGs. The prolonged response seems longer than previous data obtained with PCV alone (median of 2,7 years). Specific neurocognitive and quality of life data will be collected.
617 QFRACTURE OR PHYSICAL EXAMINATION AS SCREENING TOOLS FOR OSTEOPENIA/OSTEOPOROSIS IN A LIVER CLINIC
Authors: E. Ceriani, C. Smirne, C. Lanza, C. Ferrari, F. Caldera, R. Molinari, F. Corlianó, R. Minisini, M. Pirisi
Journal: Journal of Hepatology (2012)
P0528 : Transient elastography is safe in patients with pacemakers and implantable cardioverter-defibrillators
Authors: F. Schoelzel, S. Linzbach, F. Seeger, J. Bojunga, S. Fichtlscherer, J. Rey, E. Herrmann, A.M. Zeiher, S. Zeuzem, M. Friedrich-Rust
Journal: Journal of Hepatology (2015)